{"nctId":"NCT01323153","briefTitle":"A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)","startDateStruct":{"date":"2011-03"},"conditions":["Coronary Heart Disease"],"count":300,"armGroups":[{"label":"Dalcetrapib","type":"EXPERIMENTAL","interventionNames":["Drug: dalcetrapib"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"dalcetrapib","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult patients, \\>/=45 years of age\n* Patients admitted to the hospital for acute coronary syndrome (ACS)\n* Patients receiving guideline-based medical and dietary management of dyslipidemia\n\nExclusion Criteria:\n\n* Symptomatic congestive heart failure (NYHA Class III or IV)\n* Clinically significant heart disease requiring coronary artery bypass grafting, cardiac transplantation, surgical valve repair/replacement during the study\n* Uncontrolled hypertension\n* Uncontrolled diabetes\n* Severe anemia\n* Concomitant treatment with any other drug raising high-density lipoprotein C (HDL-C; eg niacin, fibrates)","healthyVolunteers":false,"sex":"ALL","minimumAge":"45 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in High-density Lipoprotein C (HDL-C) Levels After 4 Weeks of Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8","spread":"2.5"},{"groupId":"OG001","value":"10.1","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Similarity in Percent Change From Baseline in High-density Lipoprotein C (HDL-C) Levels After 4 Weeks of Treatment in Studies WC25501 and NC20971","description":null,"classes":[]},{"type":"SECONDARY","title":"Percent Change of High-density Lipoprotein C (HDL-C) Treatment Levels After 8, 12 and 20 Weeks of Treatment","description":null,"classes":[]},{"type":"SECONDARY","title":"Percent Change From Baseline in Blood Lipid Levels","description":null,"classes":[]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein Levels","description":null,"classes":[]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein Levels","description":null,"classes":[]},{"type":"SECONDARY","title":"Safety: Incidence of Adverse Events","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":148},"commonTop":["Diarrhoea"]}}}